Format

Send to

Choose Destination
Cell Mol Life Sci. 2017 Apr;74(8):1457-1474. doi: 10.1007/s00018-016-2412-x. Epub 2016 Nov 8.

Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.

Author information

1
Graduate School of Medical Science and Engineering, KAIST, 291 Daehak-ro, Taejon, 34141, Republic of Korea.
2
Graduate School of Medical Science and Engineering, KAIST, 291 Daehak-ro, Taejon, 34141, Republic of Korea. joonkim@kaist.ac.kr.

Abstract

A diverse range of drug resistance mechanisms in cancer cells and their microenvironment significantly reduces the effectiveness of anti-cancer therapies. Growing evidence suggests that transcriptional effectors of the Hippo pathway, YAP and TAZ, promote resistance to various anti-cancer therapies, including cytotoxic chemotherapy, molecular targeted therapy, and radiation therapy. Here, we overview the role of YAP and TAZ as drug resistance mediators, and also discuss potential upstream regulators and downstream targets of YAP/TAZ in cancer. The widespread involvement of YAP and TAZ in resistance mechanisms suggests that therapeutic targeting of YAP and TAZ may expedite the development of effective anti-resistance therapies.

KEYWORDS:

Biomarker; Drug; Hippo pathway; Resistance; TAZ; YAP

PMID:
27826640
DOI:
10.1007/s00018-016-2412-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center